Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel ...
Of more than 2,600 US healthcare workers who participated in a nationwide online panel survey from 2022 to 2023, 26% reported ...
For people with anxiety and depression, these conditions can feel like two sides of the same coin. Researchers are exploring ...
Is it anxiety or a panic attack? Discover the key differences and learn why understanding them matters for managing your ...
Cybin (NYSE American: CYBN) (NEO: CYBN) , a clinical-stage neuropsychiatry company, summarized its 2024 accomplishments and detailed upcoming 2025 m ...
Intra-Cellular recently guided to at least $5 billion in peak Caplyta sales. Intra-Cellular’s stock was trading at $127.48, up $32.61, or 34%. J&J’s stock (NYSE:JNJ) was selling for $143.39, up $1.34.
It’s hard to know how long anxiety disorders will last when you’re in the thick of them. It was during the mid-2000s that my ...
By Bhanvi Satija and Puyaan Singh (Reuters) -Johnson & Johnson said on Monday it will buy neurological drugmaker ...
Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback